Leukemias, lymphomas, and other hematologic cancers:
Indications for: Dacarbazine
Second-line therapy for Hodgkin's disease, in combination with other agents.
Adult Dosage:
Give by IV infusion. 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.
Children Dosage:
Not recommended.
Dacarbazine Warnings/Precautions:
Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Dacarbazine Classification:
Alkylating agent.
Adverse Reactions:
Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.
Note:
Formerly known under the brand name DTIC-Dome.
How Supplied:
Contact supplier
Melanoma and other skin cancers:
Indications for: Dacarbazine
Metastatic malignant melanoma.
Adult Dosage:
Give by IV infusion. 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks.
Children Dosage:
Not recommended.
Dacarbazine Warnings/Precautions:
Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Dacarbazine Classification:
Alkylating agent.
Adverse Reactions:
Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.
Note:
Formerly known under the brand name DTIC-Dome.
How Supplied:
Contact supplier
